Bezinterferonovaya therapy for hepatitis C
AbbVie largest program completed Phase III studies entirely oral, bezinterferonovogo regimen for hepatitis C genotype 1 .
99% SVR SVR12 in combination with ribavirin and without a number of categories of patients
Even in the most difficult to treat patient groups ( with cirrhosis ) achieved SVR12 at 92-96 %
AbbVie expects release of the drug to the U.S. market in 2014
NORTH CHICAGO , Ill. , Jan. 31, 2014 – AbbVie (NYSE: ABBV) announced the completion of its Phase III clinical program and published the results of four additional studies examining completely oral , bezinterferonovuyu therapy in combination with ribavirin and without patients with chronic hepatitis C genotype 1 (GT1). The results described below confirm previously published data and company AbbVie continue to show a high incidence of sustained virologic response 12 weeks after the end of treatment (SVR12), and tolerability in patients with genotype 1 . Continue reading